Tianti Biotherapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $15.7M

  • Investors
  • 5

Tianti Biotherapeutics General Information

Description

Developer of a drug discovery platform designed to improve the efficiency of antibody development. The company's platform utilizes proprietary technology to screen and build libraries of tens of millions of single B cells, enabling drug companies to improve the quality of new antibody development for muscular dystrophy and cancer.

Contact Information

Website
www.ttibio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A2-328
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • A2-328
  • Number 218 Xinghu Street
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tianti Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 13-Dec-2021 $15.7M Completed Generating Revenue
1. Seed Round 12-May-2021 Completed Startup
To view Tianti Biotherapeutics’s complete valuation and funding history, request access »

Tianti Biotherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tianti Biotherapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guangzhou Yuexiu Industrial Investment Fund Management PE/Buyout Minority
Shanghai Healthcare Capital PE/Buyout Minority
Shangshi Venture Investment Corporate Venture Capital Minority
Suzhou Oriza Holdings Corporation Asset Manager Minority
Kaitai Capital Venture Capital Minority
To view Tianti Biotherapeutics’s complete investors history, request access »

Tianti Biotherapeutics FAQs

  • When was Tianti Biotherapeutics founded?

    Tianti Biotherapeutics was founded in 2021.

  • Where is Tianti Biotherapeutics headquartered?

    Tianti Biotherapeutics is headquartered in Suzhou, China.

  • What is the size of Tianti Biotherapeutics?

    Tianti Biotherapeutics has 12 total employees.

  • What industry is Tianti Biotherapeutics in?

    Tianti Biotherapeutics’s primary industry is Drug Discovery.

  • Is Tianti Biotherapeutics a private or public company?

    Tianti Biotherapeutics is a Private company.

  • What is Tianti Biotherapeutics’s current revenue?

    The current revenue for Tianti Biotherapeutics is .

  • How much funding has Tianti Biotherapeutics raised over time?

    Tianti Biotherapeutics has raised $16.4M.

  • Who are Tianti Biotherapeutics’s investors?

    Guangzhou Yuexiu Industrial Investment Fund Management, Shanghai Healthcare Capital, Shangshi Venture Investment, Suzhou Oriza Holdings Corporation, and Kaitai Capital have invested in Tianti Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process